Dermaroller is a novel therapeutic modality in dermatology. Through physical trauma from needle penetration, dermaroller induces a wound healing cascade with mild temporary damage to the epidermis. This allows for the enhancement in the absorption of topical therapies across the thick stratum corneum. Dermaroller has become increasingly utilized over the last several years as it is a relatively simple procedure that is cost effective, well tolerated and offers cosmetic and therapeutic benefits. The ability to treat localized areas of disease made it popular in acne scars, alopecia, striae, melasma, actinic keratoses. The procedure has few adverse sequelae compared to other therapies, is highly effective and a viable resurfacing option for color of skin.

<p class="abstract">Platelet rich plasma (PRP) therapies in medicine has become increasing popular during the last decade. The interest in in the application of PRP in dermatology and cosmetology has increased recently in different applications such as alopecia, skin rejuvenation, wound healing, scar revision, and tissue regeneration. PRP is an autologous blood product obtained from the blood of the patients. The detailed knowledge about PRP should help clinicians better understand this therapy. In this view, the current review was done for a better understanding of what pathologies can be corrected with PRP.</p>

<p class="abstract">Glutathione is a potential antioxidant and its reduced form (GSH) has a good skin-whitening effect in humans through its tyrosinase inhibitory activity. Many physicians consider it as a Wonder drug for skin lightening and treatment of hyperpigmentation, especially with darker skin tones. Glutathione is available in topical, oral and injectable formulations. Topical and oral forms are considered to be safe. Intravenous form did not prove its safety and efficacy to till date. In this article, we shall review and discuss the current status of glutathione as a skin lightening agent and address the miscellaneous unanswered queries regarding the dosage, duration of use and longevity of accrued effects based on clinical evidence and recent insights into its antimelanogenic mechanism.</p>

<p class="abstract">Immunocompromised patients are at more risk in developing fungal infections particularly with <em>Candida </em>and <em>Aspergillus</em> species being the mycoses most commonly identified. Previously, amphotericin-B is the drug of choice for the treatment of systemic infections caused by <em>Candida</em> and <em>Aspergillus</em> species. Due to its high incidence of toxicity, its use has been limited in many cases. Voriconazole is the newest triazole synthesized against fungal infections and was approved by FDA in 2002 for the treatment of invasive aspergillosis and refractory infections of <em>Scedosporium apiospermum</em> and <em>Fusarium</em> spp.</p>

No abstract